Biolegend, 135023, Brilliant Violet 421™ anti-mouse CD127 (IL-7Rα) Antibody, 125microl

CD127 is a 60-90 kD type I transmembrane glycoprotein also known as IL-7 receptor α chain or IL-7Rα. It forms a heterodimer with the common γ chain (γc or CD132) which is shared with the receptors for IL-2, IL-4, IL-9, IL-13, IL-15, and IL-21. CD127 is expressed on immature B cells through early pre-B stage, thymocytes (except CD4/CD8 double positive thymocytes), peripheral T cells, and bone marrow stromal cells. CD127 has been reported to be an useful marker for identifying memory and effector T cells. The ligation of IL-7 with its receptor is important for stimulation of mature and immature T cells as well as immature B cells proliferation and development.
125microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: IL-7Ra-IgG1 fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone A7R34 is able to completely block the binding of clone S18006K to IL-7Rα. It does not block SB/199.
Additional Product Notes: View more applications data for this product in our Scientific Poster Library.
Application References(PubMed link indicates BioLegend citation): Sudo T, et al. 1993. P. Natl. Acad. Sci. USA 90:9125. Hashi H, et al. 2001. J. Immunol. 166:3702. Taylor R, et al. 2007. J. Immunol. 178:5659. Mazzon C, et al. 2011. Blood. 118:2733. PubMed Jin J, et al. 2011. J. Immunol. doi:10.4049/jimmunol.1001238. PubMed
Product Citations: Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed Michela Miani et al. 2018. Cell metabolism. 28(4):557-572 . PubMed Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed Parga-Vidal L, et al. 2022. Eur J Immunol. 52:1095. PubMed Campisi L, et al. 2022. Nature. 606:945. PubMed Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed Wang W, et al. 2022. Cell Rep. 41:111582. PubMed Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed Xu W 2023. Cell Reports. 42(1):111987. PubMed Xu R 2023. Cell Reports. 42(2):112054. PubMed Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed Sasse C, et al. 2022. Pathogens. 11:. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed Shikatani EA et al. 2019. Cell Rep. 27(8):2304-2312 . PubMed Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed Anderson CK et al. 2019. Cell Rep. 27(2):537-548 . PubMed Francian A, et al. 2021. J Drug Target. 29:754. PubMed Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed Chopin M et al. 2018. Immunity. 50(1):77-90 . PubMed He J, et al. 2020. Cell Reports. 29(9):2718-2730.e6.. PubMed Ma EH, et al. 2020. Immunity. 51(5):856-870. PubMed Zenke S, et al. 2020. Immunity. 52(2):313-327. PubMed Snell LM, et al. 2018. Immunity. 49:678. PubMed Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed Yue X, et al. 2019. Nat Commun. 10:2011. PubMed McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed Milner JJ, et al. 2020. Immunity. 52(5):808-824.e7. PubMed Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed Gagnon JD, et al. 2019. Cell Rep. 28:2169. PubMed Sheldon RD, et al. 2021. Nat Protoc. 16:4494. PubMed Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Siegemund S, et al. 2015. PLoS One. 10:124661. PubMed Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed Limbach K, et al. 2017. Malar J. 10.1186/s12936-017-1911-z. PubMed Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed Huang X, et al. 2021. Immunity. . PubMed Wang X, et al. 2021. Immunity. 54(6):1123-1136.e8. PubMed Waldman MM, et al. 2022. Front Immunol. 13:856977. PubMed
RRID: AB_10897948 (BioLegend Cat. No. 135023) AB_2563103 (BioLegend Cat. No. 135027) AB_11218800 (BioLegend Cat. No. 135024)
Structure: Type I transmembrane glycoprotein, associate with CD132, 60-90 kD
Distribution: Immature B cells through early pre-B stage, thymocytes (except CD4/CD8 double positive thymocytes), peripheral T cells, bone marrow stromal cells
Function: T cell and immature B cell proliferation and development
Ligand/Receptor: IL-7
Cell Type: B cells, T cells, Thymocytes
Biology Area: Immunology
Molecular Family: CD Molecules, Cytokine/Chemokine Receptors
Antigen References: 1. Sudo T, et al. 1993. P. Natl. Acad. Sci. USA 90:9125. 2. Okuno Y, et al. 2001. P. Natl. Acad. Sci. USA 99:6246. 3. Pillai M, et al. 2004. Leukemia Lymphoma 45:2403.
Gene ID: 16197
UniProt: View information about CD127 on UniProt.org
Clone: A7R34
Regulatory Status: RUO
Other Names: IL-7 receptor α chain, IL-7Rα
Isotype: Rat IgG2a, κ
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.